Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?

Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed...

Descripción completa

Detalles Bibliográficos
Autores principales: Piérard, Gérald E., Aubin, François, Humbert, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199197/
https://www.ncbi.nlm.nih.gov/pubmed/22046181
http://dx.doi.org/10.1155/2012/182157
_version_ 1782214540394496000
author Piérard, Gérald E.
Aubin, François
Humbert, Philippe
author_facet Piérard, Gérald E.
Aubin, François
Humbert, Philippe
author_sort Piérard, Gérald E.
collection PubMed
description Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased. The immuno-related adverse effects may be severe and life threatening.
format Online
Article
Text
id pubmed-3199197
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31991972011-11-01 Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma? Piérard, Gérald E. Aubin, François Humbert, Philippe Dermatol Res Pract Review Article Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed to CTLA-4 present on cytotoxic T cells boosts immunity, particularly its anti-MM activity. Under treatment, the overall survival of patients with MM metastases is moderately but significantly increased. The immuno-related adverse effects may be severe and life threatening. Hindawi Publishing Corporation 2012 2011-10-23 /pmc/articles/PMC3199197/ /pubmed/22046181 http://dx.doi.org/10.1155/2012/182157 Text en Copyright © 2012 Gérald E. Piérard et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Piérard, Gérald E.
Aubin, François
Humbert, Philippe
Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
title Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
title_full Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
title_fullStr Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
title_full_unstemmed Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
title_short Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
title_sort ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199197/
https://www.ncbi.nlm.nih.gov/pubmed/22046181
http://dx.doi.org/10.1155/2012/182157
work_keys_str_mv AT pierardgeralde ipilimumabapromisingimmunotherapywithincreasedoverallsurvivalinmetastaticmelanoma
AT aubinfrancois ipilimumabapromisingimmunotherapywithincreasedoverallsurvivalinmetastaticmelanoma
AT humbertphilippe ipilimumabapromisingimmunotherapywithincreasedoverallsurvivalinmetastaticmelanoma

Ejemplares similares